Key result
High residual vascular risk persists post-stroke despite secondary prevention, with ~63% maintaining uncontrolled blood pressure.
Cohort (n=302)
Yes
Answers are grounded in this paper and cite their sources.
BACKGROUND: Survivors of ischaemic stroke (IS) are at high-risk for future vascular events. Comprehensive information on the adequacy of secondary prevention after IS is lacking despite the knowledge that appropriate secondary prevention improves long-term patient outcomes. ASPIRE-S (Action on Secondary Prevention Interventions and Rehabilitation in Stroke) aimed to prospectively assess secondary prevention in patients 6 months following IS. METHODS: Consenting patients admitted with IS to three Dublin hospitals were recruited over 1 year, from October 2011. At 6 months post IS a comprehensive assessment was completed, modelled on the EUROASPIRE protocol for evaluation of the adequacy of secondary prevention in post-discharge cardiac patients. This assessment included measurements of blood pressure, body mass index and fasting lipid and glucose profiles. Secondary preventive medications and smoking status were also documented. RESULTS: Three hundred two patients (58 % male) participated, of whom 256 (85 %) were followed-up at 6 months. Mean age was 69 years (range 22-95). At follow-up, 68 % of patients had a BMI >25 kg/m(2) and 16.4 % were still smoking. Almost two-thirds (63.4 %) had a blood pressure >140/90 and 23 % had low-density-lipoprotein >2.5 mmol/L. 28 % of diabetic patients had HbA1c ≥ 7 %. Ninety seven percent of patients were on anti-platelet and/or anticoagulant therapy. Of those with atrial fibrillation, 82 % were anti-coagulated (mean INR of 2.4). Ninety-five percent were on lipid-lowering therapy and three-quarters were on anti-hypertensive therapy. CONCLUSION: This prospective multi-centre survey of IS patients demonstrated a high prevalence of remaining modifiable risk factors at 6 months post stroke, despite the widespread prescription of secondary preventive medications. There is scope to improve preventive measures after IS (in particular blood pressure) by incorporating evidence-based guidelines into quality assurance cycles in stroke care.
No takes yet. Share an insight, caveat, or question.
Brewer et al. (2015) conducted a cohort in Ischaemic stroke (n=302). Secondary prevention after ischaemic stroke was evaluated on Prevalence of modifiable risk factors and secondary preventive medication use at 6 months post-ischaemic stroke. Secondary prevention after ischaemic stroke left high residual risk at 6 months (63.4% BP >140/90, 68% BMI >25 kg/m2, 23% LDL >2.5 mmol/L) despite 97% antithrombotic and 95% lipid-lowering use.
Synapse has enriched 10 related papers. Consider them for comparative context: